Somatostatin analog

Phase 3Small molecule

UUniversity of Aarhus

Somatostatin analog is one of 59 small molecule programs targeting Fatigue. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreatic Neuroendocrine TumorActive, not recruiting

Carcinoid TumorActive, not recruiting

Pancreatic Neuroendocrine TumorPhase 3

Active, not recruiting

Carcinoid TumorPhase 2

Active, not recruiting

Competition

Competitive Landscape

60 competitors in Pancreatic Neuroendocrine Tumor

#DrugCompanyPhaseTrials

DTIC-Dome

Afinitor

8 3

Sandostatin

Glucophage

Octreotide

Sutent

5 7

FOLFOX

AstraZeneca

Phase 3

1 8

Ibrance

Pfizer

Phase 2

1 9

Sandostatin

Novartis

Phase 2

1 10

Thalomid

Bristol-Myers Squibb

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2/3Active, not recruiting

Antibiotics

NCT04329039

Q1 2027

Phase 2/3Recruiting

Statin

NCT06855095

Q2 2034

Post-ApprovalRecruiting

Statin

NCT05701241

Clinical

Trials by Indication[1]

Statin2 trials

Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA Trial

Recruiting·TThe Netherlands Cancer Institute·Phase 2/3·NCT06855095·39 enrolled

Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients

Recruiting·UUniversity Hospital, Antwerp·Phase 4·NCT05701241·270 enrolled

Treatment1 trial

Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic Patients

Completed·UUniversity of Aarhus·N/A·NCT00652379·18 enrolled

Pancreatic Neuroendocrine Tumor1 trial

Non-functioning Pancreatic Neuroendocrine Tumors in MEN1: Somatostatin Analogs Versus NO Treatment

Unknown status·MMedical University of Vienna·Phase 3·NCT02705651·180 enrolled

Antibiotics1 trial

Somatostatin Analogues With Perioperative Antibiotics Versus Prolonged Antibiotics

Active, not recruiting·MMayo Clinic·Phase 2/3·NCT04329039·103 enrolled

Fatigue1 trial

Fatigue and Quality of Life in Patients With Neuroendocrine Neoplasia

Unknown status·UUniversity of Aarhus··NCT04557137·100 enrolled

1 more indication

Carcinoid Tumor1 trial

A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors

Completed·—·Phase 2·NCT02795858·43 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Somatostatin analog. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Somatostatin analog compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Somatostatin analog. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Aarhus company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of Aarhus

Somatostatin analog

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q2 2034

Trials by Indication[1]

Statin2 trials

Treatment1 trial

Pancreatic Neuroendocrine Tumor1 trial

Antibiotics1 trial

Fatigue1 trial

Carcinoid Tumor1 trial

References

Drug Info

Quick Facts

Related News